Clin Infect Dis: Fosmycin (ZTI-01) VS The efficacy of pyridoxine-tamabatan in the treatment of complex urinary tract infections.

ZTI-01 (injected with Fosmycin) is a cyclooxide antibiotic whose differentiation mechanism (MOA) inhibits early steps in bacterial cell wall synthesis.
ZTI-01 has a wide range of active spectrums in-body, including multidring-resistant Glollath-negative pathogens, and in the United States, ZTI-01 is being developed for the treatment of complex urinary tract infections (cUTI) and acute pyelonephritis (AP).
the suspected or microbiologically proven cUTI/AP hospitalized adults were randomly assigned to 6g ZTI-01 q8h or 4.5g intravenous (IV) Pirasillin-TAZ q8h for a fixed 7-day course of treatment (not oral conversion);
results, 233 and 231 of the 465 random patients were treated with ZTI-01 and PIP-TAZ, respectively.
in the microbiologically modified intentional therapy (m-MITT) population, ZTI-01 achieved the main goal of non-poor effectiveness compared to PIP-TAZ, with a total success rate of 64.7% (119/184) patients) vs 54.5% (97/178 patients);
the evaluation of cures (TOC, 19-21 days), the clinical cure rates were high and similar in each group (90.8 per cent (167/184) vs 91.6 per cent (163/178), respectively).
post-mortem analysis of unique pathogens using pulsed field gel electrophoresis, the total success rate of m-MITT TOC was 69.0% (127/184), while PIP-TAZ was 57.3% (102/178) (difference 11.7% 95% CI:1.3, 2.1%.
ZTI-01 is well resistant.
adverse events in most treatments, including hypokalemia and elevated serum transaminase, are mild and transient.
, the results show that ZTI-01 is effective in cUTI treatment, including AP, providing a new intravenous treatment option with differentiated MOA for patients with severe Gloran negative infection.
.